Sponsor Overview
Explore verified public information about Eli Lilly and Company's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“Lilly will consider granting expanded access to an investigational medicine only if all of the following threshold criteria are met: - The patient has a serious or life-threatening illness with no comparable or satisfactory alternative therapies. - The patient is ineligible for, or otherwise unable to, participate in a clinical trial. - The patient has a disease for which there is sufficient evidence of a projected benefit from the use of the investigational medicine and the benefit outweighs the known or anticipated risks. - The investigational medicine is currently in clinical development - that is, it is currently being studied in humans. - Providing the investigational medicine for the requested use will not interfere with the initiation, conduct, or completion of clinical trials.”
Active EAPs on ClinicalTrials.gov
Score contribution: 60 — 1 supporting sources.
Conditions: Cancer
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 12 supporting sources.
Conditions: Metastatic Breast Cancer
Conditions: Soft Tissue Sarcoma
Conditions: Metastatic Gastric Cancer, Metastatic Adenocarcinoma of the Gastroesophageal Junction
Conditions: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE), Juvenile Dermatomyositis (JDM), Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI), Aicardi-Goutières Syndrome (AGS)
Conditions: Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Other Solid Tumors With Evidence of Activating RET Alteration
Conditions: Mesothelioma
Reagan-Udall Foundation Insights
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.